Study how TB medicines move through children’s bodies
Part of Infections clinical trials.
This study looks at how common TB medicines are absorbed, used, and cleared in children who are already taking treatment for tuberculosis. It may help doctors choose safer and more effective doses for children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 0 to 18 years old and has tuberculosis (TB).
- Your child is currently taking TB medicines as part of standard treatment.
- The TB treatment includes commonly used TB drugs for children.
- A parent or legal guardian can sign consent for the study.
- You can share complete medical records and the care team can safely involve your child in study steps.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients being treated for tuberculosis with standard medications to see how well the treatment works and what side effects occur. Your medical records and check-ups help doctors understand which treatments are most effective.
This study tests new ways to diagnose and monitor tuberculosis (TB) in children under 15 who might have TB in their lungs. The goal is to improve how we find and treat TB so children get better faster.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study is testing whether a shorter course of TB medicine works just as well as the standard longer treatment for children with drug-susceptible tuberculosis. It aims to make treatment easier for families.
This study is testing new ways to quickly diagnose TB in children under 15. It aims to find better tests that can be used at clinics, especially for kids who may not have obvious symptoms.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.